Xianan Guo

Hangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer.

Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer.

Journal: Cancer medicine
Published: February 27, 2026

Revisiting the standard of care for immune checkpoint inhibitors in early-stage triple-negative breast cancer: timing, duration, dose, combination, and patient selection.

Revisiting the standard of care for immune checkpoint inhibitors in early-stage triple-negative breast cancer: timing, duration, dose, combination, and patient selection.

Journal: Frontiers in immunology
Published: January 25, 2026

Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer: multicenter evidence from China.

Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer: multicenter evidence from China.

Journal: BMC cancer
Published: January 23, 2026

Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer: Striking Potential or Need for Caution?

Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer: Striking Potential or Need for Caution?

Journal: Aging and disease
Published: October 11, 2025

Recent Advances in Antibody-Drug Conjugates and Immunotherapy Combinations for Treatment of Triple-Negative Breast Cancer.

Recent Advances in Antibody-Drug Conjugates and Immunotherapy Combinations for Treatment of Triple-Negative Breast Cancer.

Journal: Breast cancer (Dove Medical Press)
Published: September 29, 2025

Management of malignant breast phyllodes tumor with rib invasion during pregnancy: a rare case report and literature review.

Management of malignant breast phyllodes tumor with rib invasion during pregnancy: a rare case report and literature review.

Journal: Frontiers in oncology
Published: September 11, 2025

Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4/6 inhibitor) plus Aromatase Inhibitors in Operable HER2-Negative Luminal B Breast Cancer: A Prospective, Single-Center, Single-Arm, Phase II Trial (DANCER).

Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4/6 inhibitor) plus Aromatase Inhibitors in Operable HER2-Negative Luminal B Breast Cancer: A Prospective, Single-Center, Single-Arm, Phase II Trial (DANCER).

Journal: MedComm
Published: March 29, 2025

Clinical significance of lipid pathway-targeted therapy in breast cancer.

Clinical significance of lipid pathway-targeted therapy in breast cancer.

Journal: Frontiers in pharmacology
Published: October 21, 2024

Predictive Significance of Systemic Immune-Inflammation Index in Patients with Breast Cancer: A Retrospective Cohort Study.

Predictive Significance of Systemic Immune-Inflammation Index in Patients with Breast Cancer: A Retrospective Cohort Study.

Journal: OncoTargets and therapy
Published: August 06, 2023

First-line CDK4/6 inhibitor-based combinations for HR+/HER2- advanced breast cancer: A Bayesian network meta-analysis.

First-line CDK4/6 inhibitor-based combinations for HR+/HER2- advanced breast cancer: A Bayesian network meta-analysis.

Journal: Journal of evidence-based medicine
Published: April 03, 2023

Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition.

Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition.

Journal: Expert opinion on investigational drugs
Published: July 05, 2022

Functional assessment of missense variants of uncertain significance in the cancer susceptibility gene PALB2.

Functional assessment of missense variants of uncertain significance in the cancer susceptibility gene PALB2.

Journal: NPJ breast cancer
Published: December 19, 2021
Showing 1-12 of 12

Last Updated: 09/26/2026